Breaking News Instant updates and real-time market news.

ABT

Abbott

09:13
10/19/16
10/19
09:13
10/19/16
09:13

Abbott sees Q4 adjusted EPS of 64c-66c, consensus 65c

Guidance from Q3 earnings call.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

LNG

Cheniere Energy

$54.73

0.29 (0.53%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Cheniere Energy, Trafigura sign 15-year LNG sale and purchase agreement »

Cheniere Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Earnings
Ultra Clean reaffirms Q4 revenue view $240.0M-$250M, consensus $244.32M »

Sees Q4 operating margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PX

Praxair

$164.15

0.34 (0.21%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Praxair expands hydrogen supply to Motiva Port Arthur, Texas refinery »

Praxair, Inc. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

, INCY

Incyte

$94.07

1.01 (1.09%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Downgrade
Concert Pharmaceuticals, Incyte rating change  »

Concert Pharmaceuticals…

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

INCY

Incyte

$94.07

1.01 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Recommendations
MGM Resorts, Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Morgan Stanley raises…

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

WYNN

Wynn Resorts

$165.54

3.04 (1.87%)

MLCO

Melco Resorts & Entertainment

$27.01

-0.21 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRWD

Ironwood

$15.12

0.02 (0.13%)

, AGN

Allergan

$176.05

-1.07 (-0.60%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Hot Stocks
Ironwood, Allergan announce settlement with Sun Pharma over LINZESS »

Ironwood Pharmaceuticals…

IRWD

Ironwood

$15.12

0.02 (0.13%)

AGN

Allergan

$176.05

-1.07 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

YUMC

Yum China

$45.86

2.06 (4.70%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
Yum China sees one-time tax expense of approximately $160M in Q4 »

Yum China Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

IO

ION Geophysical

$21.35

-2.7 (-11.23%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
ION Geophysical announces Supreme Court granted certiorari »

ION Geophysical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$67.68

0.19 (0.28%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Hot Stocks
OSI Systems signs 2-year contract to continue turnkey screening services »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Tesaro update could drive…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:31
01/16/18
01/16
08:31
01/16/18
08:31
General news
Empire State Mfg Survey General Business Conditions Index data reported »

January Empire State Mfg…

LMOS

Lumos Networks

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Lumos signs multi-year contract with Roanoke Blacksburg Regional Airport »

Lumos Networks signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.60

1.94 (2.56%)

, BOBE

Bob Evans

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Options
One new option listing and three option delistings on January 16th »

New option listings for…

WP

Worldpay

$77.60

1.94 (2.56%)

BOBE

Bob Evans

SYT

Syngenta

VNTV

Vantiv

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAWK

Blackhawk

$36.50

-0.5 (-1.35%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Blackhawk 

Blackhawk trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$257.03

1.9 (0.74%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Marcus by Goldman Sachs now offering home improvement loans »

Marcus by Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

EIGR

Eiger BioPharmaceuticals

$16.00

0.65 (4.23%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Eiger BioPharmaceuticals »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

  • 08

    Apr

GE

General Electric

$18.76

-0.26 (-1.37%)

08:29
01/16/18
01/16
08:29
01/16/18
08:29
Earnings
GE sees 2017 industrial operating & Verticals EPS at low end of $1.05-$1.10 »

Says "no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

, QGEN

Qiagen

$32.65

0.46 (1.43%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
HTG announces third statement of work for new clinical assay development program »

HTG Molecular Diagnostics…

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

QGEN

Qiagen

$32.65

0.46 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.17

-0.03 (-0.58%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
RedHill Biopharma's Phase II study of Bekinda met primary endpoint »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DERM

Dermira

$27.44

0.74 (2.77%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Recommendations
Dermira analyst commentary  »

Dermira should rally on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

, ENR

Energizer

$51.62

0.15 (0.29%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Conference/Events
Energizer to hold a conference call »

Management discusses the…

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

ENR

Energizer

$51.62

0.15 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 29

    Jan

  • 30

    Jan

  • 31

    Jan

  • 08

    Feb

TPIC

TPI Composites

$20.98

0.28 (1.35%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Initiation
TPI Composites initiated  »

TPI Composites initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WLL

Whiting Petroleum

$29.78

0.06 (0.20%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Upgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RILY

B. Riley Financial

$18.95

0.55 (2.99%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Hot Stocks
B. Riley Financial acquires 29% of bebe stores »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$10.05

-0.45 (-4.29%)

08:25
01/16/18
01/16
08:25
01/16/18
08:25
Hot Stocks
Krystal Biotech granted patent for herpes simplex viral vectors »

Krystal Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.